首页> 外文期刊>Cell death and differentiation >Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation
【24h】

Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation

机译:依赖细胞周期蛋白的激酶7和9特异性调节中性粒细胞的转录,其抑制作用可驱动细胞凋亡以促进炎症消退

获取原文
获取原文并翻译 | 示例
           

摘要

Terminally differentiated neutrophils are short-lived but the key effector cells of the innate immune response, and have a prominent role in the pathogenesis and propagation of many inflammatory diseases. Delayed apoptosis, which is responsible for their extended longevity, is critically dependent on a balance of intracellular survival versus pro-apoptotic proteins. Here, we elucidate the mechanism by which the cyclin-dependent kinase (CDK) inhibitor drugs such as R-roscovitine and DRB (5,6-dichloro-1-beta-D- ribofuranosylbenzimidazole) mediate neutrophil apoptosis. We demonstrate (by a combination of microarray, confocal microscopy, apoptosis assays and western blotting) that the phosphorylation of RNA polymerase II by CDKs 7 and 9 is inhibited by R-roscovitine and that specific effects on neutrophil transcriptional capacity are responsible for neutrophil apoptosis. Finally, we show that specific CDK7 and 9 inhibition with DRB drives resolution of neutrophil-dominant inflammation. Thus, we highlight a novel mechanism that controls both primary human neutrophil transcription and apoptosis that could be targeted by selective CDK inhibitor drugs to resolve established inflammation.
机译:终末分化的中性粒细胞寿命短,但是先天性免疫反应的关键效应细胞,并且在许多炎性疾病的发病和传播中具有重要作用。导致其延长寿命的延迟凋亡在很大程度上取决于细胞内存活与促凋亡蛋白之间的平衡。在这里,我们阐明了细胞周期蛋白依赖性激酶(CDK)抑制剂药物(例如R-rosvitvitine和DRB(5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole))介导嗜中性粒细胞凋亡的机制。我们证明了(通过微阵列,共聚焦显微镜,凋亡分析和蛋白质印迹的结合),R-roscovitine抑制了CDKs 7和9的RNA聚合酶II的磷酸化,并且对嗜中性粒细胞转录能力的特定影响是嗜中性粒细胞凋亡的原因。最后,我们显示DRB对CDK7和9的特异性抑制作用可驱动中性粒细胞显性炎症的消退。因此,我们着重介绍了一种控制原发性人类嗜中性粒细胞转录和凋亡的新型机制,该机制可通过选择性CDK抑制剂药物靶向来解决已确定的炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号